In the last trading session, 2.21 million shares of the Sarepta Therapeutics Inc (NASDAQ:SRPT) were traded, and its beta was 0.88. Most recently the company’s share price was $54.42, and it changed around -$0.21 or -0.38% from the last close, which brings the market valuation of the company to $5.28B. SRPT currently trades at a discount to its 52-week high of $173.25, offering almost -218.36% off that amount. The share price’s 52-week low was $48.01, which indicates that the current value has risen by an impressive 11.78% since then. We note from Sarepta Therapeutics Inc’s average daily trading volume that its 10-day average is 3.56 million shares, with the 3-month average coming to 1.81 million.
Sarepta Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 1 out of 27 analysts rate the stock as a Sell; another 8 rate it as Overweight. Among the rest, 4 recommended SRPT as a Hold, whereas 14 deemed it a Buy, and 0 rated it as Underweight. Sarepta Therapeutics Inc is expected to report earnings per share of -0.22 for the current quarter.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
Instantly SRPT has showed a red trend with a performance of -0.38% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 57.70 on recent trading dayincreased the stock’s daily price by 5.68%. The company’s shares are currently down -55.24% year-to-date, but still up 10.39% over the last five days. On the other hand, Sarepta Therapeutics Inc (NASDAQ:SRPT) is -46.30% down in the 30-day period. We can see from the shorts that 6.1 million shares have been sold at a short interest cover period of 2.68 day(s).
The consensus price target as assigned by Wall Street analysts is $182, which translates to bulls needing to increase their stock price by 70.1% from its current value. Analyst projections state that SRPT is forecast to be at a low of $165 and a high of $202.
Sarepta Therapeutics Inc (SRPT) estimates and forecasts
The year-over-year growth rate is expected to be 61.11%, up from the previous year.
Consensus estimates provided by 17 financial analysts predict the company will bring in an average of 684.12M in revenue for the current quarter. 17 analysts expect Sarepta Therapeutics Inc to make 745.28M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 413.46M and 362.93M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 65.46%. Forecasts for the next quarter put sales growth at 105.35%.
Sarepta Therapeutics Inc earnings are expected to increase by 73.26% in 2025, but the outlook is positive 92.98% per year for the next five years.
SRPT Dividends
Sarepta Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-25.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.42% of Sarepta Therapeutics Inc shares, and 92.31% of them are in the hands of institutional investors. The stock currently has a share float of 96.58%. Sarepta Therapeutics Inc stock is held by 654.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 10.9117% of the shares, which is about 10.32 million shares worth $1.63 billion.
VANGUARD GROUP INC, with 9.6133% or 9.04 million shares worth $1.43 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.
GROWTH FUND OF AMERICA and iShares Trust-iShares Core S&P Mid-Cap ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.16 shares worth $171.71 million, making up 3.25% of all outstanding shares. On the other hand, iShares Trust-iShares Core S&P Mid-Cap ETF held roughly 3.12 shares worth around $169.79 million, which represents about 3.22% of the total shares outstanding.
